Biotech · Private company
Astex Pharmaceuticals, Inc.
Track this companyFree. Adds Astex Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2510 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline21
- ASTX727Phase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- DacogenPhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- decitabine (5-aza-2'deoxycytidine)Phase 3 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- guadecitabinePhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- GuadecitabinePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- SGI-110 (guadecitabine)Phase 3 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- Treatment ChoicePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- Treatment ChoicePhase 3 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- Treatment Choice (TC)Phase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ASTX727 Dose ConfirmationPhase 2 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- ASTX727 Dose EscalationPhase 2 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- ASTX727 Fixed-Dose CombinationPhase 2 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- decitabine (5-aza-2'deoxycytidine)Phase 2 · Chronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Decitabine/CedazuridinePhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- GuadecitabinePhase 2 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- MagrolimabPhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- pentostatin for injectionPhase 2 · Acute Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SGI-110Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- SGI-110Phase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Early Intervention in High Risk CCUSEARLY_PHASE1 · RECRUITING · started Feb 7, 2025ClinicalTrials.gov NCT06802146 · fetched Nov 12, 2026
- A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell TransplantationPHASE2 · WITHDRAWN · started Jul 1, 2024ClinicalTrials.gov NCT06297629 · fetched Nov 12, 2026
- A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)PHASE1 · RECRUITING · started Mar 7, 2024ClinicalTrials.gov NCT06191978 · fetched Nov 12, 2026
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)PHASE2 · TERMINATED · started Jun 27, 2023ClinicalTrials.gov NCT05835011 · fetched Nov 12, 2026
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)PHASE1_PHASE2 · RECRUITING · started Oct 14, 2022ClinicalTrials.gov NCT05360160 · fetched Nov 12, 2026
- Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Feb 17, 2022ClinicalTrials.gov NCT05245682 · fetched Nov 12, 2026
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)PHASE1_PHASE2 · RECRUITING · started Nov 24, 2021ClinicalTrials.gov NCT04061421 · fetched Nov 12, 2026
- ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhasePHASE2 · ACTIVE_NOT_RECRUITING · started Oct 21, 2021ClinicalTrials.gov NCT05007873 · fetched Nov 12, 2026
- Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 19, 2021ClinicalTrials.gov NCT04655755 · fetched Nov 12, 2026
- ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant GliomasPHASE1 · RECRUITING · started Jul 12, 2019ClinicalTrials.gov NCT03922555 · fetched Nov 12, 2026
- Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 17, 2019ClinicalTrials.gov NCT03875287 · fetched Nov 12, 2026
- Guadecitabine Extension StudyPHASE2 · TERMINATED · started Jul 18, 2018ClinicalTrials.gov NCT03603964 · fetched Nov 12, 2026
- Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLPHASE3 · COMPLETED · started Feb 15, 2018ClinicalTrials.gov NCT03306264 · fetched Nov 12, 2026
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 4, 2017ClinicalTrials.gov NCT03220477 · fetched Nov 12, 2026
- Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsPHASE1 · COMPLETED · started Mar 20, 2017ClinicalTrials.gov NCT03019003 · fetched Nov 12, 2026
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaPHASE3 · COMPLETED · started Mar 16, 2017ClinicalTrials.gov NCT02920008 · fetched Nov 12, 2026
- Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsPHASE3 · COMPLETED · started Jan 13, 2017ClinicalTrials.gov NCT02907359 · fetched Nov 12, 2026
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionPHASE3 · COMPLETED · started Mar 19, 2015ClinicalTrials.gov NCT02348489 · fetched Nov 12, 2026
- Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)PHASE1_PHASE2 · COMPLETED · started Oct 28, 2014ClinicalTrials.gov NCT02103478 · fetched Nov 12, 2026
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)PHASE2 · COMPLETED · started Dec 1, 2012ClinicalTrials.gov NCT01752933 · fetched Nov 12, 2026
- SGI-110 in Combination With Carboplatin in Ovarian CancerPHASE2 · COMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01696032 · fetched Nov 12, 2026
- SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)PHASE1_PHASE2 · COMPLETED · started Jan 4, 2011ClinicalTrials.gov NCT01261312 · fetched Nov 12, 2026
- Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)PHASE2 · COMPLETED · started Jul 1, 2002ClinicalTrials.gov NCT00042003 · fetched Nov 12, 2026
- Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHDPHASE1_PHASE2 · TERMINATED · started Jan 30, 2002ClinicalTrials.gov NCT00032773 · fetched Nov 12, 2026
- Decitabine Versus Supportive Care in Adults With Advanced-stage MDSPHASE3 · COMPLETED · started Apr 1, 2001ClinicalTrials.gov NCT00043381 · fetched Nov 12, 2026